As your browser does not support javascript you won't be able to use all the features of the website. We strongly recommend you to enable the javascript in your old browser's settings or download a new one.

Pamplona Capital Management nears deal to buy Parexel: source

FILE PHOTO: A view of the U.S. drug research company, Parexel International Corp office in Uxbridge, north London, March 15, 2006.

Private equity firm Pamplona Capital Management LLP is nearing a deal to acquire U.S. pharmaceutical research services provider Parexel International Corp for more than $4.5 billion, a person familiar with the matter said on Tuesday.

Activist investors, including Starboard Value LP, have put pressure on Parexel to explore a sale, arguing that the company's profit margins have consistently lagged those of its peers.

The deal will be announced later on Tuesday, the source said. Pamplona is set to pay $88.10 per share in cash for Parexel, the Wall Street Journal reported earlier on Tuesday...